Mythic Therapeutics Presents Trial in Progress Poster on Investigational cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 at American Society of Clinical Oncology (ASCO) Annual Meeting
The Phase 1 KisMET-01 clinical trial enrolls patients with locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC) Waltham, Mass.,
0 Comments